** U.S.-listed shares of Biofrontera Inc fall 11% to 74 cents
** On Wednesday, company reported Q3 rev. of $9 mln, missing two analysts' average est. of $10 mln, due to disruption from hurricanes
** Q3 loss of 98 cents/shr wider than est. loss of 84 cents/shr, according to data compiled by LSEG
** BFRI likely to report strong Q4 revenue, as demand for Ameluz, company's treatment for a type of skin condition, increases in less-sunny weather - Brokerage Roth MKM
** Company to also benefit from Ameluz price hike of October and hurricane-interrupted sales moving into the quarter - Roth MKM
** Including session gains, BFRI down 73.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。